Correlation Between Circulating Leptin Level with Left Ventricle Mass in Normotensive Men

Abstract

Background.Obesity is one of Cardiovascular risk factor. Obesity caused increase in heart mass due to cellular hypertrophic and metaplastic proses, independently of hemodynamic factors such as blood pressure. There were hyperleptinemia in obesity due to the selective Leptin resistency in central nervous system and peripheral organs. Study with cultured rat cardiomyocyte have shown hypertrophy and hyperplastic effect of Leptin to cardiomyocyte. Some clinical studies have shown correlation between circulating Leptin level with Left Ventricle Mass in hypertensive and insulin resistance men.
Objective. This study aimed to elaborate the correlation between circu-lating Leptin level with Left Ventricle Mass in normotensive men.
Methods. A cross sectional study was performed with normotensive men, which included 40 obese normotensive and 40 normoweight men. All patients underwent physical and laboratory assessment and examination of Left Ventricle with echocardiography. The circulating Leptin level were determined by ELISA method. The Leptin level were expressed as median (25th percentile; 75th percentile)
Results. The circulating Leptin level were significantly different between the obese normotensive and the lean group. The Left Ventricle Mass in Obese increased, although have not fulfilled the criteria for Left Ventricle Hypertrophy. There were significant correlation between Left Ventricle Mass with BMI (r = 0,711; p<0,001) and waist circumference (r = 0,732; p<0,001). Respectively, there were significant correlation between Left Ventricle Mass Index with BMI (r = 0.541; p<0.001) and waist circumfer-ence (r = 0,558; p<0.001. There were significant correlation between circulating Leptin level with Left Ventricle Mass (r = 0,510; <0,001) and Left Ventricle Mass Index (r = 0,414; p<0,001) in obese men.
Conclusion.Circulating Leptin level is correlated with Left Ventricle Mass in normotensive men.

Downloads

Download data is not yet available.

References

Eckel RH, York DA, Rossner S, Hubbard V, Caterson I, St Jeor ST, dkk. American Heart Association. Prevention Conference VII: obesity, a worldwide epidemic related to heart disease and stroke: executive summary. Circulation. 2004; 110: 2968–75.

Poirier P, Giles TD, Hong Y, Bray GA, Stern JS, Eckel RH, dkk. Obesity and Cardiovascular Disease: Pathophysiology, Evaluation and Effect of weight loss. Arterioscler Thromb Vasc Biol. 2006; 26: 968-76.

Wilson PW, D’Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002; 162: 1867-72.

Sowers JR. Obesity and Cardiovascular disease. Clinical Chemisty. 1998; 44 8(b): 1821-25.

Tasic IS, Lovic BK, Ilic S, Djordjevic D, Miladinovic N. Relationship between obesity decrease and regression of hypertensive left ventricular hypertrophy. Facta Universitatis. 2002; 9: 181-7.

Heymsfield S, Hoffman D, Testolin C, Wang Z. Evaluation of human adiposity. Dalam: Bjorntorp P, editor. International textbook of obesity. New York: John Wiley & Sons, Ltd; 2001.p.85-97.

Houseknecht KL, Baile CA, Matteri RL, Spurlock M. The biology of Leptin: a review. J Anim Sci. 1998; 76(5): 1405-20.

Bjorbaek C, Kahn B. Leptin signaling in the central nervous system and the periphery. Recent Prog Horm Res. 2004; 59(1):305-31.

Rahmouni K, Haynes G. Leptin and the Cardiovascular system. Endocrinology. 2004; 225-43.

Ren J. Leptin and hyperleptinemia – from friend to foe for cardiovascular function. Journal of Endocrinology. 2004; 181:1-10.

Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, dkk. Plasma Leptin and the risk of Cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 2001; 104: 3052-6.

Leyva F, Anker SD, Egerer K, Stevenson JC, Kox WJ, Coats AJ. Hyperleptinaemia in chronic heart failure: relationships with insulin. Eur Heart J. 1998; 19: 1547-51.

Katz M. Maladptive growth in the failling heart: the cardiomyopathy of overload. Cardiovasc Drugs Ther. 2002; 16:245-9.

Mazumder PK, O’Neill BT, Roberts MW, Buchanan J, Yun UJ, Cooksey RC, dkk. Impaired cardiac efficiency and increased fatty acid oxidation in insulin resistant ob/ob mouse hearts. Diabetes. 2004; 53: 2366-74.

Quehenberger P, Exner M, Sunder-Plassman R, Ruzicka K, Endler G, Muellner C, dkk. Leptin induces endothelin-1 in endothelial cels in vitro. Circulation Research. 2002;90: 711-8.

Boulumie A, Marumo T, Lafontan M, Busse AR. Leptin induces oxidative stress in human endothelial cells. FASEB J. 1999; 13:1231-8.

Xu FP, Chen MS, Wang YZ, Yi Q, Lin SB, Chen AF, dkk. Leptin induces hypertrophy via endothelin-1 reactive oxygen species pathway in cultured neonatal rat cardiomyocytes. Circulation. 2004; 110: 1269-75.

Pallan S. Effects and mechanisms of action of Leptin on cardiomyocytes. J of Young Invest.2005; 12: 1-13.

Adiarto S, Emoto N, Iwasa N, Yokoyama M. Obesity induced upregulation of myocardial endothelin-1 expression is mediated by leptin. Biochemical Biophysical Research Comunications. 2007;353: 623-7.

Malmqvist K, Ohman KP, Lind L, Nystrom F, Kahan T. Relationships between left ventricular mass and the renin-angiotensin system, catecholamines, insulin and leptin. J of Int Med. 2002; 252: 430-9.

Paolisso G, Tagliamonte MR, Galderisi M, Zito GA, Petrocelli A, Carella C, dkk. Plasma leptin level is associated with myocardial wall thickness in hypertensive insulin-resistant men.Hypertension. 1999; 34: 1047-52.

Kanazawa M, Yoshiike N, Osaka T, Numba Y, Zimmet P, Inoue S. Criteria and Classification of obesity in Japan and Asia-Oceania. Asia Pasific J Clin Nutr. 2002; 11: S7 32-7.

Subekti I, Yunir E, Soebardi S, Semiardji G, Oemardi M, Soewondo P. Studi prevalensi DM dan faktor risiko yang berhubungan di desa Abadi Jaya Depok. Dalam: Buku abstrak KONAS VI Perkeni. Medan.2003.

Alpert MA. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am J Med Sci. 2001; 321: 225-36.

Ku CS, Lin SL, Wang DJ, Chang SK, Lee WJ. Left ventricular filling in young normotensive obese adults. Am J Cardiol. 1994; 73: 613-5.

Pluim BM, Van der Laarse A, Vliegen HW, Bruschke AV, Van der Wall EE. Left ventricular hypertrophy: pathology versus physiology. Dalam: Van der Wall EE, ed. Left Ventricular Hypertrophy. Leiden. 1999; Kluwer academic publications.

Lorell BH, Carabello BA. Left Ventricular Hypertrophy. Pathogenesis, detection and prognosis. Circulation. 2000; 102: 470-9.

Sasson Z, Rasooly Y, Gupta R, Rasooly I. Left atrial enlargement in healthy obese: prevalence and relation to left ventricular mass and diastolic function. Can J Cardiol. 1996; 12: 257-63.

Wang DJ, Parise H, Levy’D, D’Agostino RB,Wolf PA, Vasan RS, dkk. Obesity and the risk of new onset atrial fibrillation. JAMA. 2004; 292: 2471-7.

Coleman DL. Effects of parabiosis of obese with diabetes and normal mice. Diabetologia. 1973; 9: 294-8.
Views & Downloads
Abstract views: 64   
PDF (Bahasa Indonesia) downloads: 1   
How to Cite
Correlation Between Circulating Leptin Level with Left Ventricle Mass in Normotensive Men. (1). Indonesian Journal of Cardiology, 28(5), 343-353. https://doi.org/10.30701/ijc.v28i5.220
Section
Clinical Research